Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Am J Kidney Dis. 2022 Oct 11;81(3):329–335. doi: 10.1053/j.ajkd.2022.08.014

Table 2.

Associations of Clonal Hematopoiesis of Indeterminate Potential with 30% Decline in eGFR.

CHIP Number of participants Number of eGFRs (IQR) Median follow-up time, years (IQR) Number of events Incidence per 100 person-years Unadjusted HR (95% CI) Adjusted* HR (95%CI)
ARIC Yes 584 3 (3,4) 9 (8,22) 143 2.20 1.23 (1.04,1.46) 1.20 (1.01, 1.43)
No 5,991 3 (3,4) 9 (8,23) 1,392 1.94 reference reference
CHS Yes 240 3 (2,3) 7 (3,7) 40 2.14 1.48 (1.02, 2.13) 1.38 (0.92, 2.06)
No 1,461 3 (2,3) 7 (4,7) 216 1.53 reference reference
MESA Yes 178 4 (4, 4) 9 (9, 10) 22 1.44 0.99 (0.64, 1.52) 0.85 (0.55, 1.30)
No 3,550 4 (4, 4) 9 (9, 10) 433 1.39 reference reference
Meta-Analysis Yes 1,002 3 (3,4) 8 (7, 14) 205 2.05 1.24 (1.07, 1.43) 1.17 (1.01, 1.36)
No 11,002 3 (3,4) 8 (7, 15) 2,041 1.71 reference reference
p = 0.004 p = 0.036

ARIC = Atherosclerosis Risk in Communities Study; CHS = Cardiovascular Health Study; MESA = Multi-Ethnic Study of Atherosclerosis; CHIP = Clonal hematopoiesis of indeterminate potential; eGFR = estimated glomerular filtration rate.

*

Adjusted for age, age-squared, sex, baseline eGFR, diabetes, and log-urine albumin to creatinine ratio (where available at baseline).